3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
59
Neoplasm Metastasis
24
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Adenocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Salivary Gland Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Solid Cancer
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasm, Residual
1
Interventions
Paclitaxel
114
Carboplatin
114
Cisplatin
45
Topotecan
43
Gemcitabine
31
Cyclophosphamide
31
Docetaxel
28
liposomal doxorubicin
27
Bevacizumab
27
Filgrastim
20
pembrolizumab
19
Peripheral Blood Stem Cell Transplantation
18
Taxes
15
Drug Therapy
15
sargramostim
12
Hyperthermic Intraperitoneal Chemotherapy
12
olaparib
11
Chemotherapy, Adjuvant
10
Surgical Procedures, Operative
9
Etoposide
9
oregovomab
8
mirvetuximab soravtansine
8
Nivolumab
8
Amifostine
8
Therapeutics
7
Melphalan
7
Erlotinib Hydrochloride
7
rucaparib
6
aldesleukin
6
Oxaliplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled